Fluidigm Corp (FLDM): Levin Capital Strategies Reports 25.2% Stake

Page 1 of 20

According to a recent 13D filing with the SEC, John A. Levin‘s Levin Capital Strategies has increased its stake in Fluidigm Corp (NASDAQ:FLDM) to 7.32 million common shares, which account for 25.2% of the company’s outstanding stock. The fund’s stake has been raised from 5.69 million shares, which accounted for 19.6% of the float, as per its previous 13G filing on the company, dated September 30. While the latest filing was on a Form 13D, the fund has not gone activist on the stock, maintaining that its investment remains passive and that its 20% stake necessitated filing a 13D.

Fluidigm Corporation is a company that manufactures new technologies for biological research purposes. Since the beginning of the year, the company’s stock has lost 57.45%. For the second quarter of 2016, Fluidigm disclosed a loss per share of $0.64 and revenue of $28.2 million, worse results than the loss per share of $0.53 and revenue of $28.6 million that it pulled in for the same quarter of the previous year. Recently, Cantor Fitzgerald reiterated its ‘Buy’ rating on Fluidigm Corporation’s stock but lowered its price target on it to $9 from $11.

trade, forex, investment, gain, stock, phone, network, view, report, money, smart, background, broker, market, laptop, table, economy, display, loss, business, urban,


12 investors from within Insider Monkey’s database reported holding long positions in Fluidigm Corp (NASDAQ:FLDM) as of the end of June, down from 14 hedge funds at the end of March. Among the bullish smart money managers of the stock were Jim Simons’ Renaissance Technologies, which held a position valued at $2.35 million, Brian Ashford-Russell and Tim Woolley’s Polar Capital, with a $489,000 position, and Samuel Isaly’s OrbiMed Advisors.

Follow Standard Biotools Inc. (NASDAQ:LAB)

Investors who lost enthusiasm for investing in Fluidigm Corp (NASDAQ:FLDM) and cut their positions during the second quarter encompassed Hal Mintz’s Sabby Capital, which said goodbye to a $1.3 million position, Michael Vranos’ Ellington, which sold a position valued at $171,000 at the end of March, Paul Marshall and Ian Wace’s Marshall Wace LLP, and Ken Griffin’s Citadel Investment Group.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Levin Capital Strategies 0 5,478,118 0 7,317,390 7,317,390 25.2%
Levin Capital Strategies GP 0 5,478,118 0 7,317,390 7,317,390 25.2%
Levin Capital Trilogy Master Fund, Ltd 0 51,068 0 51,068 51,068 Less than 1%
LCS 0 51,068 0 51,068 51,068 Less than 1%
Levcap Alternative Fund 0 22,453 0 22,453 22,453 Less than 1%
LCS Event Partners 0 22,453 0 22,453 22,453 Less than 1%
Safinia Partners 0 9,252 0 9,252 9,252 Less than 1%
LCS L S 0 9,252 0 9,252 9,252 Less than 1%
John A. Levin 0 5,478,118 0 7,317,390 7,317,390 25.2%

Follow John A. Levin's Levin Capital Strategies

Page 1 of 20 – SEC Filing

Washington, D.C. 20549
(Rule 13d-101)
§ 240.13d-2(a)
(Amendment No.  )1
Fluidigm Corporation
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
(CUSIP Number)
John A. Levin
Levin Capital Strategies, L.P.
595 Madison Avenue, 17th Floor
New York, NY 10022
(212) 259-0800

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)
October 13, 2016
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.
Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.
1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 1 of 20